Purpose: Recognizing Osteoporosis and Its Consequences in Québec revealed that 73% of women 50y and over are not provided anti-fracture therapy following fragility fracture. This study’s objectives were to determine predictors of osteoporosis (OP) diagnosis (DX) and treatment (TX) 6 to 8 months after fragility fracture.

Method: At phase 1, women were recruited at cast or out-patient clinics within 16 weeks post-fracture. Consenting patients answered a short questionnaire classifying them as experiencing a fragility or traumatic fracture; no reference to the association between fracture and OP was made and no investigation or intervention was proposed. At phase 2, 6–8 months post-fracture, the women completed a questionnaire on demographic features, clinical characteristics and risk factors for OP. The DX (informed of OP and/or BMD measurement with diagnosis of OP) and TX (bisphosphonates, raloxifene, nasal calcitonin or teriparatide) rates of OP were determined via this questionnaire. This analysis included only women with a fragility fracture who were not receiving OP TX at phase 1.

Results: Of the 1273 women completing phase 1, 1001 (79%) sustained a fragility fracture; 818 were untreated at phase 1 and completed the phase 2 questionnaire. Overall, 79% of these participants had not received a DX of osteoporosis or were without OP TX at phase 2. The highest rate of DX and TX of OP occurred 0–5 months post-fracture and decreased considerably thereafter. In multivariate analyses, the results of BMD tests before or after the fracture event (p< 0.0001) and mobility problems (p=0.03) were the only variables that influenced the DX of OP. BMD test results were the strongest predictor (p< 0.0001) of TX followed by the fracture site (hip, femur and pelvis; p=0.015) and administration of vitamin D supplements at the time of fracture (p=0.035). No other risk factors for OP significantly influenced the DX or TX rate. No demographic or clinical features or OP risk factors were significantly associated with the decision to refer women for BMD testing post-fracture.

Conclusion: Although fragility fracture represents a greater risk of future fragility fracture than low BMD, physicians based their decision to treat on BMD and not the clinical event (fragility fracture).

Health utilities indicate the value of a given health state. They are essential components of decision analyses, and economic evaluations. In the area of total shoulder arthroplasty (TSA) we were unable to find literature estimating changes in utilities or the effect of method of obtaining utilities. The purpose of this pilot study was to describe the trajectory of utility scores before and after TSA using three approaches: the EQ-5D and the Health Utilities Index (HUI2 and HUI3) self-report format.

Twenty-four patients undergoing TSA at two teaching hospitals (Boston and Toronto) were assessed twice preoperatively, as well as at four and twelve weeks follow-up by self report mailed survey. At each survey all three utility estimates were obtained. Demographic and functional status was also gathered. The EQ-5D is a five item questionnaire which scores into a profile to which utility weights obtained from the developers were applied. The HUI self-report is a fifteen item scale obtaining a score on eight domains. A multiplicative formula is used to assign utility weights to these responses. Descriptive analysis of the sample, baseline characteristics and change in utility were completed. Intra-class correlation coefficients were used to calculate test-retest reliability between the two preoperative visits. Standardised response means (SRM) (mean change/SD of change) and relative efficiency (RE=ratio of SRM2) were calculated. Individual trajectories of change were graphed and examined for trends.

Twenty-four patients participated with average age of sixty-seven years, 58% were female and experienced large improvements in disability and pain (mean change DASH = 18.9/100, SPADI Pain = 30.3/100). Utility scores had low to moderate correlations with each other (0.26–0.68). Mean baseline scores were low (EQ5D=0.44, HUI2=0.68, HUI3 = 0.50). The average change in utility is shown in the following table along with effect size estimations and test-retest reliability.

Patients experience clinically important and statistically significant changes in their utility values even in the early stages of recovery after TSA (three months). The HUI3 and EQ-5D were most responsive to changes experienced in this sample.